Success of Centralized Manufacturing of CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML

We describe feasibility of centralized manufacturing for CD33 CAR T-cell products (CD33CART) on the dose-escalation part of a multicenter Phase I/II clinical trial in children and adolescents/young adults (AYA) with r/r AML (NCT03971799).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Brian Bowser, Xiaoyi Yang, John Roach, Julie Blake, Kate Donnelly, Brenna Paskey, Heidi VanBockel, Bonnie Yates, Chloe Hoang, Sarah K Tasian, Katherine Tarlock, Susanne H.C. Baumeister, Emily M. Hsieh, Michael R. Verneris, Hati K Kobusingye, Allison Weiss Tags: 198 Source Type: research